Alzheimer's drug trial halted early: what we know
NCT ID NCT05478031
First seen Jan 08, 2026 · Last updated May 13, 2026 · Updated 22 times
Summary
This study tested an experimental drug called REM0046127 in people with mild to moderate Alzheimer's disease. Participants took either a high dose, low dose, or placebo for 28 days. The goal was to check safety and see how the drug affected brain signals and spinal fluid markers. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BRC Amsterdam
Amsterdam, Amsterdam, 1081, Netherlands
-
FISEVI Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Fundacion ACE
Barcelona, 08029, Spain
Conditions
Explore the condition pages connected to this study.